Kelly E Crowe1, Guohong Shao2, Kevin M Flanigan2,3, Paul T Martin2,3. 1. Graduate Program in Molecular Cellular and Developmental Biology, The Ohio State University, Columbus, OH, USA. 2. Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. 3. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Abstract
BACKGROUND: Duchenne Muscular Dystrophy (DMD) is a severe, progressive, neuromuscular disorder of childhood. While a number of serum factors have been identified as potential biomarkers of DMD, none, as yet, are proteins within the dystrophin-associated glycoprotein (DAG) complex. OBJECTIVE: We have developed an immobilized serum ELISA assay to measure the expression of a constitutively cleaved and secreted component of the DAG complex, the N-terminal domain of α dystroglycan (αDG-N), and assayed relative expression in serum from muscular dystrophy patients and normal controls. METHODS: ELISAs of immobilized patient or mouse serum and Western blots were used to assess αDG-N expression. RESULTS: Immobilization of diluted serum on ELISA plates was important for this assay, as methods to measure serum αDG-N in solution were less robust. αDG-N ELISA signals were significantly reduced in DMD serum (27±3% decrease, n = 9, p < 0.001) relative to serum from otherwise normal controls (n = 38), and calculated serum αDG-N concentrations were reduced in DMD relative to normal (p < 0.01) and Becker Muscular Dystrophy (n = 11, p < 0.05) patient serum. By contrast, ELISA signals from patients with Inclusion Body Myositis were not different than normal (4±3% decrease, n = 8, p = 0.99). αDG-N serum signals were also significantly reduced in utrophin-deficient mdx mice as compared to mdx and wild type mice. CONCLUSIONS: Our results are the first demonstration of a component of the DAG complex as a potential serum biomarker in DMD. Such a serum measure could be further developed as a tool to help reflect overall muscle DAG complex expression or stability.
BACKGROUND:Duchenne Muscular Dystrophy (DMD) is a severe, progressive, neuromuscular disorder of childhood. While a number of serum factors have been identified as potential biomarkers of DMD, none, as yet, are proteins within the dystrophin-associated glycoprotein (DAG) complex. OBJECTIVE: We have developed an immobilized serum ELISA assay to measure the expression of a constitutively cleaved and secreted component of the DAG complex, the N-terminal domain of α dystroglycan (αDG-N), and assayed relative expression in serum from muscular dystrophypatients and normal controls. METHODS: ELISAs of immobilized patient or mouse serum and Western blots were used to assess αDG-N expression. RESULTS: Immobilization of diluted serum on ELISA plates was important for this assay, as methods to measure serum αDG-N in solution were less robust. αDG-N ELISA signals were significantly reduced in DMD serum (27±3% decrease, n = 9, p < 0.001) relative to serum from otherwise normal controls (n = 38), and calculated serum αDG-N concentrations were reduced in DMD relative to normal (p < 0.01) and Becker Muscular Dystrophy (n = 11, p < 0.05) patient serum. By contrast, ELISA signals from patients with Inclusion Body Myositis were not different than normal (4±3% decrease, n = 8, p = 0.99). αDG-N serum signals were also significantly reduced in utrophin-deficient mdx mice as compared to mdx and wild type mice. CONCLUSIONS: Our results are the first demonstration of a component of the DAG complex as a potential serum biomarker in DMD. Such a serum measure could be further developed as a tool to help reflect overall muscle DAG complex expression or stability.
Authors: Jerry R Mendell; Louise R Rodino-Klapac; Zarife Sahenk; Kandice Roush; Loren Bird; Linda P Lowes; Lindsay Alfano; Ann Maria Gomez; Sarah Lewis; Janaiah Kota; Vinod Malik; Kim Shontz; Christopher M Walker; Kevin M Flanigan; Marco Corridore; John R Kean; Hugh D Allen; Chris Shilling; Kathleen R Melia; Peter Sazani; Jay B Saoud; Edward M Kaye Journal: Ann Neurol Date: 2013-09-10 Impact factor: 10.422
Authors: V D Nadarajah; M van Putten; A Chaouch; P Garrood; V Straub; H Lochmüller; H B Ginjaar; A M Aartsma-Rus; G J B van Ommen; J T den Dunnen; P A C 't Hoen Journal: Neuromuscul Disord Date: 2011-07-02 Impact factor: 4.296
Authors: Sonia Covaceuszach; Manuela Bozzi; Maria Giulia Bigotti; Francesca Sciandra; Petr Valeryevich Konarev; Andrea Brancaccio; Alberto Cassetta Journal: FEBS Open Bio Date: 2017-07-17 Impact factor: 2.693
Authors: Jessica C de Greef; Bram Slütter; Mary E Anderson; Rebecca Hamlyn; Raul O'Campo Landa; Ellison J McNutt; Yuji Hara; Lecia L Pewe; David Venzke; Kiichiro Matsumura; Fumiaki Saito; John T Harty; Kevin P Campbell Journal: Proc Natl Acad Sci U S A Date: 2019-05-16 Impact factor: 11.205